Patents by Inventor Yuval Avnir

Yuval Avnir has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190276519
    Abstract: The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.
    Type: Application
    Filed: January 28, 2019
    Publication date: September 12, 2019
    Inventors: Wayne A. Marasco, Yuval Avnir
  • Patent number: 10179822
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69. This antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: January 15, 2019
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
  • Publication number: 20170174751
    Abstract: The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.
    Type: Application
    Filed: March 19, 2015
    Publication date: June 22, 2017
    Inventors: Wayne Marasco, Yuval Avnir
  • Publication number: 20170073431
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69. This antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
    Type: Application
    Filed: November 11, 2016
    Publication date: March 16, 2017
    Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
  • Patent number: 9527924
    Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: December 27, 2016
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
  • Publication number: 20150093434
    Abstract: Provided are pharmaceutical compositions including a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between ?2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between ?2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.
    Type: Application
    Filed: December 4, 2014
    Publication date: April 2, 2015
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERSUSALEM
    Inventors: Yechezkel BARENHOLZ, Alberto A. GABIZON, Yuval AVNIR
  • Patent number: 8932627
    Abstract: The present invention provides pharmaceutical compositions comprising a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between ?2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between ?2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.
    Type: Grant
    Filed: September 11, 2005
    Date of Patent: January 13, 2015
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Yechezkel Barenholz, Alberto A. Gabizon, Yuval Avnir
  • Publication number: 20130243749
    Abstract: Disclosed is a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VHI-69. The antibody is derived from Mab G6 and recognizes the same epitope. Moreover, the antibody is used in combination with vaccines to augment an immune response to the antigen.
    Type: Application
    Filed: June 2, 2011
    Publication date: September 19, 2013
    Applicant: Dana Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Jianhua Sui, Yuval Avnir
  • Patent number: 7744920
    Abstract: The present invention provides the use of a glucocorticoid (GC) or of a GC derivative encapsulated in a liposome for the preparation of a pharmaceutical composition for the treatment of an inflammatory associated condition in a subject, provided that said condition is not associated with a neurodegenerative disease or disorder. A specific use concerns a liposomal formulation comprising methylprednisolone sodium hemisuccinate (MPS) for the treatment of rheumatoid arthritis.
    Type: Grant
    Filed: September 11, 2005
    Date of Patent: June 29, 2010
    Assignees: Hadasit Medical Research Services & Development Limited, Yissum Research Development Company of the Hebrew University
    Inventors: Yechezkel Barenholz, Yaakov Naparstek, Yuval Avnir, Rina Ulmansky
  • Publication number: 20080058294
    Abstract: The present invention provides pharmaceutical compositions comprising a glucocorticoid or glucocorticoid derivative stably encapsulated in a liposome. The glucocorticoid or glucocorticoid derivative is selected from an amphipathic weak base glucocorticoid or glucocorticoid derivative having a pKa equal or below 11 and a logD at pH 7 in the range between ?2.5 and 1.5; or an amphipathic weak acid GC or GC derivative having a pKa above 3.5 and a logD at pH 7 in the range between ?2.5 and 1.5. The therapeutic effect of the pharmaceutical composition of the invention was exhibited in vivo with appropriate models of multiple sclerosis and cancer.
    Type: Application
    Filed: September 11, 2005
    Publication date: March 6, 2008
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Yechezkel Barenholz, Alberto Gabizon, Yuval Avnir
  • Publication number: 20080003276
    Abstract: The present invention provides the use of a glucocorticoid (GC) or of a GC derivative encapsulated in a liposome for the preparation of a pharmaceutical composition for the treatment of an inflammatory associated condition in a subject, provided that said condition is not associated with a neurodegenerative disease or disorder A specific use concerns a liposomal formulation comprising methylprednisolone sodium hemisuccinate (MPS) for the treatment of rheumatoid arthritis.
    Type: Application
    Filed: September 11, 2005
    Publication date: January 3, 2008
    Inventors: Yechezkel Barenholz, Yaakov Naparstek, Yuval Avnir, Rina Ulmansky